Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 812-244-2 | CAS number: 957209-18-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
- Report date:
- 2013
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- 1996
- Deviations:
- yes
- Principles of method if other than guideline:
- Deviations: The liver weights of male no. 15 (recovery group 1) and female no. 100 were not determined and a few tissues were not available for histopathology. Sufficient data was available for evaluation.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 2,3,3,4,4-pentafluoro-2,5-bis(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-5-methoxyoxolane
- EC Number:
- 812-244-2
- Cas Number:
- 957209-18-6
- Molecular formula:
- C11H3F19O2
- IUPAC Name:
- 2,3,3,4,4-pentafluoro-2,5-bis(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-5-methoxyoxolane
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: 3M Company, Batch: L-21343
- Expiration date of the lot/batch: 27 August, 2014
- Purity test date: 27 August, 2012
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: At room temperature in the dark.
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: The test article was dosed undiluted.
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on species / strain selection:
- Wistar Han sources from Charles River Deutschland, Sulzfeld, Germany.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany.
- Females (if applicable) nulliparous and non-pregnant: Yes
- Age at study initiation: Approximately 11 weeks
- Weight at study initiation: Male mean: 323.5 g, Female mean: 208.5 g
- Fasting period before study: not specified.
- Housing: Pre-mating: animals were housed in groups of 5/sex/cage in Macrolon plastic cages (MIV type, heigh 18 cm). This was also applicable for Recovery animals throughout the complete study eriod. Mating: Main females were caged together with Main males on a one-to-one basis in Macrolon plastic cages (MIII type, height 18 cm). Post-mating: Main males were housed in their home cage (Macrolon plastic cages, MIV type, height 18 cm) with a maximum of 5 animals per cage. Main females were individually housed in Macrolon plastic cages (MIII ype, height 18 cm). Lactation: Pups were kept with the dam until termination in Macrolon plastic cages (MIII type, height 18 cm). During locomotor activity monitoring of the dams, the pups were kept warm in their home cage using bottles filled with warm water.
- Diet (e.g. ad libitum): Pelleted rodent diet (SM R/M-Z from SSNIFF), ad libitum.
- Water (e.g. ad libitum): Tap water, ad libitum.
- Acclimation period: At least 5 days prior to the start of treatment.
ENVIRONMENTAL CONDITIONS
- Temperature (°C):18-24
- Humidity (%): 40-70
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 17 October, 2012 To: 28 December, 2012
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: The test article was dosed unchanged.
- Analytical verification of doses or concentrations:
- no
- Remarks:
- Test article was dosed unchanged so the initial purity verification was sufficient.
- Duration of treatment / exposure:
- All rats were exposed once daily for 7 days per week; all males were exposed for a total of 29 days, including 2 weeks of exposure prior to mating and during mating for rats in the 4 main groups, and all females were exposed for a total of 41-47 days prior to mating, during mating, during post mating, and lactation periods. Males in the recovery groups were allowed to recover for 14 days following the last exposure.
- Frequency of treatment:
- All rats were exposed once daily for 7 days per week; all males were exposed for a total of 29 days, including 2 weeks of exposure prior to mating and during mating for rats in the 4 main groups, and all females were exposed for a total of 41-47 days prior to mating, during mating, during post mating, and lactation periods. Males in the recovery groups were allowed to recover for 14 days following the last exposure.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw (total dose)
- Remarks:
- Control animals were dosed with water.
- Dose / conc.:
- 100 mg/kg bw (total dose)
- Dose / conc.:
- 300 mg/kg bw (total dose)
- Dose / conc.:
- 1 000 mg/kg bw (total dose)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale: Based on a range-finding study.
- Rationale for animal assignment (if not random): Random
- Rationale for selecting satellite groups: Random
- Post-exposure recovery period in satellite groups: 14 Days - Positive control:
- None
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Daily
BODY WEIGHT: Yes
- Time schedule for examinations: First day of exposure and weekly thereafter.
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes, weekly.
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Week 4
- Dose groups that were examined: 5 Main animals/sex/group and all Recovery animals.
HAEMATOLOGY: Yes
- Time schedule for collection of blood: On the day of necropsy
- Anaesthetic used for blood collection: Yes (isofluorane)
- Animals fasted: Yes
- How many animals: 5 Main animals/sex/group and all Recovery animals.
- Parameters checked: white blood cell count, differential leucocyte count, red blood cell count, red blood cell distribution width, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin concentration, platelets, prothrombin time, activated partial thromboplastin time
CLINICAL CHEMISTRY: Yes
Time schedule for collection of blood: On the day of necropsy
- Anaesthetic used for blood collection: Yes (isofluorane)
- Animals fasted: Yes
- How many animals: 5 Main animals/sex/group and all Recovery animals.
- Parameters checked: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, albumin, total bilirubin, urea, creatinine, glucose, cholesterol, sodium, potassium, chloride, calcium, inorganic phosphate, bile acids
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: Week 4
- Dose groups that were examined: The selected Main males and all Recovery males were tested during Week 4 of treatment and the selected Main females were tested towards the end of the scheduled lactation period (all before blood sampling) (from lactation Day 4 onwards) and all Recovery females were tesed on the first day a Main female was tested. Since no treatment-related findings were noted in any of the above tests, these tests were not conducted for Recovery animals at the end of the recovery phase.
- Battery of functions tested: sensory activity / grip strength / motor activity / other:
IMMUNOLOGY: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
Histopathology included adrenal glands, brain, colon, duodenum, eyes, female mammary gland area, femur including joint, heart, ileum, jejunum, kidneys, liver, lung, lymph nodes, peyer's patches, pituitary gland, rectum, sciatic nerve, skeletal muscle, spinal cord, spleen, sternum with bone marrow, stomach, thymus, thyroid, trachea, urinary bladder, cervix, clitoral gland, coagulation gland, epididymides, ovaries, preputial gland, prostate gland, seminal vesicles, testes, uterus, and vagina.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No clinical signs of toxicity related to the test article were noted in any animal.
- Mortality:
- no mortality observed
- Description (incidence):
- No treatment related mortality occurred during the study period.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No toxicologically relevant changes in body weight and body weight gain were noted.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- no effects observed
- Description (incidence and severity):
- Food consumption before or after allowance for body weight was similar between treated and control animals.
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- Pupillary reflex was normal in all selected animals tested in the FOB.
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Hematological parameters of treated rats were considered not to have been affected by treatment.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Clinical biochemistry parameters of treated rats were considered not to have been affected by treatment.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- Hearing ability, pupillary reflex, static righting reflex and grip strength were normal in all selected animals.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- No toxicologically relevant changes were noted in organ weights and organ to body weight ratios.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Macroscopic observations at necropsy did not reveal any alterations that were considered to have arisen as a result of treatment.
- Neuropathological findings:
- no effects observed
- Description (incidence and severity):
- Hearing ability, pupillary reflex, static righting reflex and grip strength were normal in all selected animals.
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- There were no treatment-related microscopic findings.
- Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- There were no treatment-related microscopic findings.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 1 000 mg/kg bw (total dose)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- behaviour (functional findings)
- body weight and weight gain
- clinical biochemistry
- clinical signs
- food efficiency
- gross pathology
- haematology
- histopathology: neoplastic
- histopathology: non-neoplastic
- mortality
- ophthalmological examination
- organ weights and organ / body weight ratios
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- Based on the results of the study, the test article has a No Observed Adverse Effect Level of 1000 mg/kg/day.
- Executive summary:
The repeated dose oral toxicity potential and the reproductive / developmental toxicity potential of the test article was evaluated in male and female Wistar Han rats via daily oral gavage for 28 days. The study was performed in compliance with OECD GLP (1997). The study design was based on OECD 422 (1996) and US EPA OPPTS 870.3650 (2000), and essentially conforms to OECD 421 (1995), US EPA OPPTS 870.3550 (2000), EC 440/2008 Part B B7. L142 (2008), OECD 407 (2008), and US EPA OPPTS 870.3050 (2000). The test article was dosed undiluted and given at a dose volume of 0.055-0.553 mL/kg to four groups of rats by oral gavage. Rats (10/sex/group) were dosed with 0, 100, 300, and 1000 mg/kg-body weight test article per day. Additional rats (5 males/group) were exposed at 0 mg/kg-day or 1000 mg/kg-day for a recovery study. All rats were dosed once daily for 7 days per week; all males were exposed for a total of 29 days, including 2 weeks of exposure prior to mating and during mating for rats in the 4 main groups, and all females were exposed for a total of 41-47 days prior to mating, during mating, during post mating, and lactation periods. Males in the recovery groups were allowed to recover for 14 days following the last dose. Observational parameters evaluated in all main and recovery groups rats included; mortality (twice daily), clinical signs (daily), body weights (first day of exposure and weekly thereafter), food consumption (weekly), and general reproduction data (during mating and post-mating). Pups born to mating mothers were evaluated for mortality (daily), clinical signs (at least once daily), body weights (Days 1 and 4 of lactation), and sex determination (Days 1 and 4 of lactation). Hematology, clinical biochemistry, necropsy, and histopathology and organ weight collection were performed on selected tissues of rats in the main exposure groups (5/sex/group). Histopathology included adrenal glands, brain, colon, duodenum, eyes, female mammary gland area, femur including joint, heart, ileum, jejunum, kidneys, liver, lung, lymph nodes, peyer's patches, pituitary gland, rectum, sciatic nerve, skeletal muscle, spinal cord, spleen, sternum with bone marrow, stomach, thymus, thyroid, trachea, urinary bladder, cervix, clitoral gland, coagulation gland, epididymides, ovaries, preputial gland, prostate gland, seminal vesicles, testes, uterus, and vagina. No treatment related mortality occurred during the study period. No clinical signs of toxicity related to the test article were noted in any animal. Hearing ability, pupillary reflex, static righting reflex and grip strength were normal in all selected animals tested in a functional observational battery. No toxicologically relevant changes in body weight and body weight gain were noted. Food consumption before or after allowance for body weight was similar between treated and control animals. Hematological and clinical biochemistry parameters of treated rats were considered not to have been affected by treatment. Macroscopic observations at necropsy did not reveal any alterations that were considered to have arisen as a result of treatment. No toxicologically relevant changes were noted in organ weights and organ to body weight ratios. There were no treatment-related microscopic findings. No toxicologically relevant effects on reproductive parameters were noted. No toxicologically relevant effects on gestation index and duration, parturition, maternal care and postnatal pup development were observed. Based on the results of the study, the test article has a No Observed Adverse Effect Level of 1000 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.